Read this company snapshot
Daily valuation snapshot
BeOne Medicines Ltd. American Depositary Shares: source evidence dated 2026-10-09.
- Daily close (USD)
- $354.47
- Market capitalization (USD)
- $40,303,904,449.26
- Price / earnings (TTM)
- 61.47
- Price / book
- 7.79
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research ONC in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research ONC in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
BeOne Medicines Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; Ociperlimab (BGB-A1217), a TIGIT inhibitor; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines Ltd. in May 2025. BeOne Medicines Ltd. was incorporated in 2010 and is based in Basel, Switzerland.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing ONC with another company.
Scroll sideways to compare all columns. Select a heading to sort.
| Daily close (USD) | $354.47 |
| Market capitalization (USD) | $40,303,904,449.26 |
| Price / earnings (TTM) | 61.47 |
| Price / book | 7.79 |
No matching rows. Clear the filter to see all records.
Read ONC's valuation metrics
Company size
BeOne Medicines Ltd. American Depositary Shares's recorded market capitalization is $40,303,904,449.26. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
ONC's recorded P/E is 61.47: about $61.47 of share price for each $1 of trailing annual earnings per share. Compare that multiple with earnings growth and companies in the same business.
Price relative to book equity
ONC's recorded price-to-book ratio is 7.79. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research BeOne Medicines Ltd. American Depositary Shares with Aurora
Use the snapshot above to ask a specific question about ONC. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow ONC's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.